drugset / Trial / NCT00089895

EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)

NCT00089895

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention (surgery) compared to placebo (with delayed provisional use of eptifibatide).

Timeline

Start
2004-11-01
Primary completion
2008-11-01
Completion
2008-11-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Eptifibatide Other / unclassified 2 ug/kg Intravenous